Breaking News

Financial Report: BASi

August 14, 2014

Service revenues up 14% in the quarter


3Q Revenues: $6.0 million (+8%)

3Q Earnings: $215,000 (-63%)

YTD Revenues: $18.2 million (+10%)

YTD Loss: $666,000 (earnings were $521 million YTD13)

Comments: Service revenue in the quarter increased 14% to $4.8 million primarily due to higher toxicology revenue, offset slightly by lower bioanalytical analysis revenue. Product revenue decreased 12% to $1.3 million. Earnings in the quarter and YTD were affected by non-cash decreases in the fair value of warrant liability of $66,000 and $1.1 million, respectively.
blog comments powered by Disqus
  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • Platinum Press Facility Tour

    Platinum Press Facility Tour

    Kristin Brooks, Contract Pharma||March 23, 2016
    Opens doors to new, 47,000-sq.-ft. packaging facility in Oakland, NJ

  • Biopharma Packaging Equipment Close-up

    Biopharma Packaging Equipment Close-up

    Kristin Brooks, Contract Pharma||March 7, 2016
    Sieghard Schuchmann of OPTIMA discusses biopharma trends impacting packaging equipment, and the latest capabilities

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Four Pillars to Guide Your CRO Search

    Four Pillars to Guide Your CRO Search

    Alan Findlater , WIL Research||November 17, 2015
    Tips on how to seek out the best possible CRO-Sponsor relationship

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies